Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Paradigm Biopharmaceuticals Ltd. has issued 40 million fully paid ordinary shares without disclosure under the Corporations Act, affirming compliance with all relevant regulations. The Melbourne-based company is focused on advancing its late-stage drug developments, particularly its injectable treatment for diseases like osteoarthritis and mucopolysaccharidosis.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.
